Effect of Sarcopenia in Stroke Patients
Study Details
Study Description
Brief Summary
Primary research purpose:
-Prospective study to screen post stroke patients with sarcopenia and evaluate its effect on recovery
Secondary research purpose:
-
To determine the degree of sarcopenia and correlation with poor functional prognosis of stroke in the stroke patient group.
-
To determine the degree of sarcopenia and correlation with dixon MRI of thigh muscle
-
To evaluate surface EMG (SEMG)-based signals and correlation with sarcopenia
-
To determine the degree of sarcopenia and correlation with brain morphometric changes
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Patients with first-ever stroke will be enrolled and assessed for sarcopenia. The evaluation parameters will include standard sarcopenia parameters and also SEMG-based signals and imaging studies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Stroke patients with sarcopenia Group will be stratified according to gender |
Diagnostic Test: DEXA Scan
Fu of diagnostic tests
Other Names:
|
| Stroke patients without sarcopenia Group will be stratified according to gender |
Diagnostic Test: DEXA Scan
Fu of diagnostic tests
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change of Modified Rankin Scale [6 months from the first onset of the stroke]
Functional Disability -> The scale runs from 0-6, running from perfect health without symptoms(0) to death(6).
Secondary Outcome Measures
- Hand grip strength [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
Grip strength: Grip strength will be measured using a dynamometer
- quadriceps muscle strength [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
Lower extremity strength assessment:change in isometric quadriceps muscle strength (kg) from initial evaluation to the final evaluation
- Fugl-Meyer motor scale [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
Motor function assessment : Fugl-Meyer motor scale from initial evaluation to the final evaluation (Upper Extremity maximum score = 66; Lower Extremity maximum score = 34, Higher score means better outcome)
- Functional Ambulation Category [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
Gait function assessment : Functional Ambulation Category from initial evaluation to the final evaluation (Minimum 0, Maximum 5; Higher score means better outcome)
- Berg balance scale [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
Balance function: change in Berg balance scale from initial evaluation to the final evaluation (Minimum score 0, Maximum score 56, Higher score means better outcome)
- Brain MRI [within 4 weeks and 6 months from the first onset of the stroke]
Brain atrophy : change in the Global cortical atrophy scale(0-3) of the cerebral cortex from initial evaluation to the final evaluation
- Thigh Dixon MRI [within 4 weeks and 6 months from the first onset of the stroke]
Muscle quality : muscle circumference measured by the thigh MRI from initial evaluation to the final evaluation
- Muscle ultrasonography [within 4 weeks and 6 months from the first onset of the stroke]
muscle thickness(cm) measured by the ultrasound of the quadriceps muscle from initial evaluation to the final evaluation
- serum biomarkers for sarcopenia [within 4 weeks from the first onset of the stroke]
BNDF, IL-6
- Digitalized SEMG signals [within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke]
state of the art EMG signals will be collected to assess muscle quality changes after stroke
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients 65 years of age or older, stroke patients with first onset within 4 weeks
Exclusion Criteria:
-
Patients who have not been evaluated for sarcopenia
-
Patients with neuromuscular diseases other than stroke that may affect gait function
-
Patients unable to conduct clinical trials according to instructions
-
Patients with uncontrolled medical/surgical disease
-
Patients with metal substances in the body such as cardiac pacemakers, cochlear implants, etc.
-
Patients who have difficulty collecting blood
-
Patients who are difficult to follow up after 6 months of onset due to moving to another area
-
Patients who have Parkinson's disease, dementia, or have a history of neuromuscular diseases such as Guillain-Barré syndrome or myasthenia gravis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Catholic University of Korea | Bucheon-si, Gyeonggi-do | Korea, Republic of | 14647 | |
| 2 | St. Vincent's Hospital | Suwon-si | Korea, Republic of | 16247 |
Sponsors and Collaborators
- The Catholic University of Korea
- Saint Vincent's Hospital, Korea
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VC22ONDI0185